ScanSource SCSC Q3 2026 Earnings Call Transcript

ScanSource reported 9% year-over-year consolidated net sales growth and stronger profitability, with Specialty Technology Solutions gross profit up 10% to $81 million and adjusted EBITDA up 6% to $24.7 million. Free cash flow was $69 million for the quarter, lifting year-to-date free cash flow to $119 million, and management raised FY2026 free cash flow guidance to at least $90 million while maintaining revenue and adjusted EBITDA outlooks. The company is also launching a Converged Communications business unit and highlighted AI-enabled CX wins, but Intelisys net sales declined 1% year over year and management wants faster new-order growth.

Analysis

The key read-through is not the headline growth, but the change in mix of the franchise. Management is effectively admitting the legacy lower-multiple, transaction-oriented portion of the business is no longer enough to carry the story, so they are reorganizing around a convergence thesis that can slow customer churn and raise attach rates across hardware, cloud, and services. That matters because it shifts the valuation conversation from cyclical distribution to an integrated workflow platform, but the market will need proof that organizational restructuring translates into materially better new-order conversion before awarding a rerating.

The second-order effect is on the competitive set: a more unified go-to-market model can improve wallet share with existing partners faster than it can win entirely new ones, which means the near-term upside is likely to show up first in cross-sell, not top-line acceleration. That creates a lagging but real operating lever for the next 2-6 quarters, while the explicit 6-18 month revenue lag on investments suggests the main benefit may land in FY27 rather than FY26. The cash generation and repurchase cadence also reduce equity downside, but they can mask weak organic momentum if billings fail to inflect.

The risk case is that the current strength is partly a mix-driven margin tailwind rather than a durable demand step-up. If the new order engine does not accelerate, the company could enter FY27 with good reported profitability but a softer backlog-quality narrative, which would cap multiple expansion. In that scenario, any disappointment in large-deal timing would likely hit the stock quickly because the market is already being asked to underwrite a longer-duration transformation story.

Contrarian angle: this is less a 'beat-and-raise' compounding story than a capital-allocation and operating-leverage story with a delayed payoff. The consensus may be overestimating how quickly AI-enabled CX and converged sales motions can move the needle, while underestimating how much buybacks and balance-sheet cleanliness can support the stock during the transition. The setup favors patience: if management delivers even modest order acceleration over the next two quarters, the rerating could be outsized from a low starting multiple.

Key Decisions for Investors

• Long SCSC on a 3-6 month horizon only on pullbacks toward support, with the thesis centered on free-cash-flow support and buyback downside protection; target a re-rating if FY27 order growth shows clear acceleration.
• Sell out-of-the-money SCSC calls 3-6 months out against a long equity position to monetize elevated uncertainty around FY27 guidance and the 6-18 month execution lag.
• Pair trade: long SCSC / short a more cyclical distributor with weaker recurring revenue mix, betting that capital returns plus convergence-led mix shift outperform pure hardware beta over the next 2 quarters.
• If you want a cleaner catalyst trade, wait for the next quarterly call and buy SCSC only if management confirms new-order acceleration in Intelisys; otherwise treat it as a range-bound value trap with a strong balance sheet.